Viragen hat wieder einen Investor gefunden, der Viragen Aktien gekauft hat. Damit hat man die Finanzierung bis ins Jahr 2005 gesichert. Der Kurs reagiert verhalten positiv: aktuell 0,26 US$ (+0,01 US$)
Viragen Announces New Round Of Equity Financing
PLANTATION, Fla., Dec. 30 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the biotechnology Company received approximately $4.2 million in a sale of its common stock and warrants completed with a group of new and returning institutional investors. The Company intends to use the proceeds to commercialize its lead drug, Multiferon(TM), and further the research and development of its portfolio of healthcare technologies.
"I expect to report that our calendar year-`end balance sheet has significantly improved," stated Dennis W. Healey, Viragen`s Chief Financial Officer. "Based on Senior Management`s efforts to cut overhead and operating costs this year, this funding strengthens our cash position to provide working capital into 2005 as we execute our business plan. Also, I believe our financial position has been further strengthened this quarter through the conversions of all outstanding debentures related to previous financings thus eliminating that debt. Our solidified financial foundation should prove advantageous as we continue to seek to attract new partners and investors."
The complete terms of financing will be filed via a Form 8-K with the Securities and Exchange Commission (SEC). The document will be available at the SEC`s website at http://www.sec.gov and Viragen`s website at http://www.Viragen.com
|aus der Diskussion:||Viragen - aktueller Artikel im Science Magazin|
|Autor (Datum des Eintrages):||Frakt@l (30.12.03 18:02:35)|
|Beitrag:||72 von 128 (ID:11712374)|
|Alle Angaben ohne Gewähr © wallstreet:online|